To assess the signaling pathways involved in CAPE treatments in prostate carcinoma cells, we treated PC-3 cells with CAPE to determine the activities of ERK, p38, JNK, and AMPKα1/2. This evidence concerns the gene MAPK8 and prostate carcinoma.